What I do at MMV:
I steer the Plasmodium vivax team’s efforts to conduct different feasibility studies and support policy adoption processes in endemic countries.
Why I work at MMV:
My professional choices have been driven by the potential to positively and substantially impact on the clinical management of underserved patients, addressing treatment needs that for-profit entities largely ignored. MMV has been leading the path in the development and roll-out of antimalarials, with the prospect to impact disease burden and contribute to eradication. It is extremely exciting for me to contribute to this unique mission and be part of an incredibly diverse and experienced team.
More about me:
I hold a Ph.D. in Molecular Biology from the University of Geneva and a Master in Epidemiology from the London School of Hygiene and Tropical Medicine (LSHTM). Throughout the past 15 years, I have gained experience in planning and conducting multinational clinical studies in both high- and low-resource settings.
I started my career as a Clinical Research Associate (CRA) in the Division of Humanitarian and Tropical Medicine of Geneva University Hospitals, focusing on infectious diseases and supporting both epidemiological studies and interventional trials. I became affiliated with the Clinical Research Center (CRC), which allowed me to gain knowledge and experience in therapeutic and diagnostic trial planning, conduct, and reporting under ICH GCP. At the CRC, I was asked to lead the setup and launch of two post-graduate diplomas: the DAS in Management of Clinical Trials and the MAS in Drug Discovery and Clinical Development.
In 2013 I moved to Médecins Sans Frontières (MSF) as the Clinical Trial Manager of a large trial on Multi-Drug Resistant Tuberculosis (MDR-TB) that investigated two new antibiotics in combination with other existing antibiotics. In August 2016 I joined the Global Antibiotics Research and Development Partnership (GARDP) as Program Leader for the Sexually Transmitted Infections Program. My role as a cross-functional program lead entailed overseeing all research and development activities necessary to support registration of the first-in-class antibiotic with US, EU, Thai, and South Africa regulatory authorities.
Ask me about:
Clinical trials and epidemiology; Research Ethics; Hiking and birdwatching.